GLP-1 receptor agonists , particularly those like BrightMeds, are rapidly gaining prominence in the management of type 2 diabetes and are increasingly explored for metabolic conditions. These powerful drugs work by mimicking the body's natural incretin hormone , stimulating glucose-dependent insu